Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%

MT Newswires Live

03/19

Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.

The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.

IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.

Its shares jumped 5% in recent trading on Thursday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2620292812"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620292812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620292812?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620292812","market":"sg","top_or_hot":-1,"title":"Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.</p><p>The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.</p><p>IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.</p><p>Its shares jumped 5% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-19 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.</p><p>The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.</p><p>IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.</p><p>Its shares jumped 5% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620292812","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620292812","pubTimestamp":1773883807,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","IMM.AU":"IMMUTEP LTD"},"translate_title":"Immutep完成一期自身免疫性疾病候选疗法研究的单次递增剂量部分；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}